Icon

ZEPZELCA (nda213702)- (4MG/VIAL)

LURBINECTEDIN JAZZ
4MG/VIAL
Yes No
2029-Dec-13 2025-Jun-15
None None
None No
ZEPZELCA is an alkylating drug indicated for the treatment of adult patients with metastatic small cell lung cancer (SCLC) with disease progression on or after platinum-based chemotherapy.
0 0 0
Total Other Developers 7
Drugs with Suitability No
4MG/VIAL ** ** - - -
NDA Sales Available Total Generic Sales Available
Yes 0
ANDA No Generic Co Manufacturer Name Operations Manufacturer Address Country

Download GenUS Drug Report


Download GenUS Detailed Report


To get detailed report Contact Us

GenUs Advanced Search




Expired
to
Expired
to


Brand Name Generic Name Strength Dosage Route of Administration Innovator ParaIV

Please contact contact@researchdelta.com to get more details.